Top Dental School Receives ADEA Grant to Use Pearl's AI Platform to Improve Radiologic Education and Clinical Performance for High-Quality, Consistent Patient Care
'It is terrific to see UCLA taking a leading role in the AI-driven advancement of dental education,' said Ophir Tanz, founder and CEO of Pearl. 'The ADEA grant empowers faculty and students with a tool designed specifically to foster consistency and higher standards in radiologic diagnosis –– and underscores AI's increasingly vital influence on dentistry today. In collaboration with UCLA, we are making significant strides toward a dental future where AI and human talent blend to elevate care and foster better outcomes for patients.'
'At UCLA, we are committed to embracing innovation that safely and securely advances our field,' said Dr. Paul H. Krebsbach, Dean of the UCLA School of Dentistry. 'Implementing this new technology aligns with our strategic imperative to leverage best-in-class digital architecture and to prepare our students to lead in the evolving landscape of dental care. I commend Dr. Sanjay Mallya, chair of our Section of Oral and Maxillofacial Radiology, for leading this initiative.'
Calibrate is a multi-purpose tool that helps a broad range of users hone their dental x-ray evaluation skills and overcome subjectivity endemic to diagnostic radiology. Calibrate helps ensure consistency across clinical professionals operating within dental industry organizations including universities, single- and multi-site clinics, radiology centers, and insurance companies. Offering an extensive internal image library, as well as the ability to upload image datasets, Calibrate allows administrators to prescribe interpretive standards and customize benchmarks tailored to their organizations' unique clinical specifications.
About Pearl
Pearl is an AI-driven company committed to enhancing patient care in dentistry. Founded in 2019 by a team with decades of experience developing successful, enterprise-grade computer vision solutions, Pearl introduced the first-ever FDA-cleared AI capable of reading and instantly identifying diseases in dental x-rays. With regulatory clearance in 120 countries, Pearl's AI assists dentists in making precise clinical decisions and effectively communicating with patients, thereby transforming the dental care experience worldwide. As dentistry's global AI leader, Pearl is committed to the ongoing innovation of robust, accessible AI tools that improve patient health outcomes and build greater trust in dental medicine. To request a demo, please visit hellopearl.com/getdemo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
New at-home lab test gives postpartum mothers real answers—before the six-week checkup
A postpartum care revolution that finally puts moms first. America's postpartum experience is broken. By the time a mother finally sees her OB at six weeks postpartum, she's already endured some of the hardest weeks of her entire life with little medical oversight. In my case, after my first child was born I was in excruciating urethra pain that I thought was normal, because there was no doctor's visit to catch it. For other moms, postpartum depression plagues their first few weeks of motherhood. Other women experience the crisis of postpartum preeclampsia without medical oversight, trying to determine if their symptoms are normal or intervention-worthy. What if moms were screened far before a medical crisis occurs postpartum? That's the promise behind a new innovation from Trellis Health: the first FDA-cleared, at-home postpartum lab panel designed specifically to catch health issues before they spiral. Created by moms for moms, this tool fills a critical gap in maternal healthcare and provides medically actionable insights. Related: This new at-home program is redefining postpartum care for moms The postpartum data cliff is real—and dangerous Here's the current reality: Women receive rigorous testing throughout pregnancy. But once the baby arrives, all that data collection… disappears. According to the American College of Obstetricians and Gynecologists (ACOG), the first 40 days after giving birth are critical to a mother's long-term health—yet our system treats them like a footnote. Roughly 1 in 5 mothers will experience a postpartum mood disorder. Up to 10% will face thyroid dysfunction. Half of women with gestational diabetes will develop type 2 diabetes within five years. Yet many won't receive a single lab test between delivery and the standard six-week checkup. 'We test hundreds of biomarkers during pregnancy. Then we test nothing,' said Trellis Health co-founder and CEO Dr. Estelle Giraud. 'That's a healthcare failure.' A test designed for the way moms actually live For $239 (HSA/FSA eligible), the Trellis test offers a finger-to-fridge solution: a painless blood collection patch you stick to your upper arm. In ten minutes, it collects a sample to analyze more than 30 biomarkers—from thyroid function and hormone levels to inflammation and cardiovascular risk. Results arrive within 3–4 days and integrate directly into the Trellis app, which serves as a digital 'care in your pocket' with asynchronous midwife support and a full health timeline. 'Six weeks is a perfect moment to catch things like nutrient deficiencies before they spiral into fatigue, mood, and lactation issues,' Giraud said in an interview with The Bump. Related: Why nutrition is the missing piece in postpartum care Why this is a lifeline For moms managing naps, cluster feeds, and toddler tantrums, the idea of booking labs, securing childcare, and making it to a clinic is often laughable. And for those with limited healthcare access—rural families, single moms, uninsured patients—Trellis could be the only lab work they receive during this vulnerable window. 'I had gestational diabetes, and this was easier than my CGMand this is easier than my CGM [Continuous Glucose Monitoring]—the whole process was simple and so straightforward,' said beta tester Amara Bell. Experts urge thoughtful use—but recognize its potential Dr. Christine Greves, an OB-GYN at Orlando Health Women's Institute, told The Bump she's excited by the test's proactive potential, especially since over half of maternal deaths occur after delivery and most are preventable. But she also cautions that hormone levels in postpartum bodies are naturally in flux and that test results should always be interpreted in partnership with a trusted provider. In other words: Data is powerful—but it's still just a starting point. A test—and a message—that puts women in charge This test is a wake-up call for a healthcare system that treats birth like a finish line instead of a starting point. For too long, postpartum recovery has been framed as a private struggle. Moms are told to 'listen to their bodies' but given no tools to actually understand them. Trellis flips that script by putting clinical-grade insight into a mom's own hands. What you can do now: Bring this data to your six-week checkup: Ask about iron, thyroid, and vitamin D levels. Request follow-ups if anything feels off. If you're pregnant or postpartum you can pre-order the test at Financial hardship options are available; email support@ to apply. Advocate for systemic change: Paid leave, universal postpartum check-ins, and real investment in maternal health shouldn't be optional. Because 'just tired' should never be the answer when something deeper is going on. Sources: New At-Home Lab Test Closes Gap In Postpartum Care. 2025. Forbes. New At-Home Lab Test Closes Gap In Postpartum Care. First At-Home Postpartum Lab Test Aims to Empower Moms. 2025. The Bump. First At-Home Postpartum Lab Test Aims to Empower Moms. Postpartum risk for type 2 diabetes following gestational diabetes mellitus: A systematic review and meta-analysis. 2022. Preventing Chronic Disease (CDC). Postpartum risk for type 2 diabetes following gestational diabetes mellitus. Postpartum Thyroiditis: Diagnosis and Management. 2020. Endocrine Abstracts. Postpartum Thyroiditis. Maternal Mental Health Conditions and Statistics. 2025. Maternal Mental Health Leadership Alliance. Maternal Mental Health Conditions and Statistics. Optimizing Postpartum Care. 2018. American College of Obstetricians and Gynecologists. Optimizing Postpartum Care.
Miami Herald
an hour ago
- Miami Herald
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Cash burn of $3.8 million in Q2 remains in line with projected quarterly range - Cash and investments are sufficient to fund operations through Q3'2026 at current cash burn rate - Commercial readiness activities underway for a phased launch of VenoValve® subject to FDA decision expected in 2H'2025 - IDE submission for enVVe® on track for 2H'2025 IRVINE, CA / ACCESS Newswire / August 1, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the second quarter 2025. "As the recent headlines around CVI confirmed, CVI is a pervasive and a progressive disease that is especially debilitating once it becomes severe. Our participation in several of the recent national news stories about CVI fits with our strategy of establishing enVVeno Medical as the world-wide leader in treatments for severe, deep venous disease. With several value driving milestones on the horizon, including FDA decisions on potential approval for the VenoValve and the pivotal study for enVVe, we continue to make strong progress in our mission to bring first-in-category, effective treatments to patients with severe CVI, and are well positioned to lead the ongoing national dialogue about CVI as further events are reported," commented Robert Berman, CEO of enVVeno Medical. Summary of Financial Results for the Second Quarter 2025The Company ended the quarter with $35.1 million in cash and investments. Based on management's current expectations, this capital has the potential to fund the Company through the third quarter of 2026, including pre-commercialization activities for the VenoValve, and the commencement of the enVVe pivotal study. Cash burn for the quarter was $3.8 million, consistent with the Company's projected cash burn rate of approximately $4-5 million per quarter. The Company anticipates that its cash burn rate will increase from current levels once commercialization of the VenoValve begins. The Company reported net losses of $6.7 million and $5.0 million for the three months ended June 30, 2025 and 2024, respectively, representing an increase in net loss of $1.7 million, or 35%. This increase was primarily due to higher operating expenses of $1.6 million resulting from additional personnel costs, the issuance of option grants, and non-recurring reserve and severance expenses, as well as a decrease in other income of $0.1 million. Clinical Program ProgressVenoValve®: Novel, First-In-Class Surgical Replacement Venous Valve Amended VenoValve PMA application in response to formal questions from U.S. Food and Drug Administration (FDA)Continue to respond to FDA questions and inquiries as they arisePresented positive interm, two-year data at Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingPMA decision from FDA expected 2H'2025 enVVe®: Novel, First-In-Class Non-Surgical Transcatheter-Based Replacement Venous Valve Successfully completed final wave for the shorter-term subjects in 6-month pre-clinical GLP studyAwaiting final pathology form the GLP studySuccessfully completed other testing necessary for IDE filingIDE filing for enVVe pivotal trial on track for 2H'2025 President Trump CVI DiagnosisFollowing President Trump's recent diagnosis of what appears to be moderate CVI, Dr. Marc Glickman, Senior Vice President and Chief Medical Officer of enVVeno Medical was featured in several national television news segments, podcasts, radio reports, and news articles, including Fox News, NewsMax, Morning Wire, and the N.Y. Post. To view this media, click here. About enVVeno Medical CorporationenVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking StatementsThis press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. ### INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
Yahoo
2 hours ago
- Yahoo
Freeze dried fruit sold at Sam's Club recalled due to listeria
Doehler Dry Ingredient Solutions, LLC is recalling boxes of Member's Mark freeze dried fruit due to potential listeria contamination, which can lead to serious illness. In an alert Friday, the U.S. Food and Drug Administration said the company discovered the problem affecting some 15-count boxes of "Member's Mark Freeze Dried Fruit Variety Pack" after internal product testing. So far, no illnesses have been reported. The recalled boxes are marked with UPC 1 93968 50900 2 and included varied lot codes and use-by dates, which can be found listed on the FDA's website. The product was distributed between July 1 and July 25, 2025, and sold in Sam's Club retail stores in 42 states, which are listed below. Officials are urging people not to eat the product. Consumers should discard it and visit any Sam's Club for a full refund, the FDA says. Listeria infections are caused by eating food contaminated with a bacteria called Listeria monocytogenes. Symptoms can include high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, the FDA said. The Centers for Disease Control and Prevention warns that people may also experience a stiff neck and flu-like symptoms, such as muscle aches and fatigue. Some people are at higher risk of severe cases and even death, including those who are pregnant, newborns, adults 65 or older, and those with weakened immune systems. Here is the list states where the products were sold: AlabamaArizonaCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIowaIdahoIllinoisIndianaKansasLouisianaMarylandMaineMichiganMinnesotaMissouriMississippiMontanaNorth CarolinaNorth DakotaNebraskaNew HampshireNew JerseyNew MexicoNevadaNew YorkOhioOklahomaPennsylvaniaSouth CarolinaSouth DakotaTennesseeTexasUtahVirginiaWisconsinWest VirginiaWyoming Consumers with questions may contact the company's customer service department at 1-770-387-0451, Monday through Friday, from 8 a.m. to 5 p.m. ET. Arkansas officials reveal new details about Devil's Den murders of husband and wife Diamond Dallas Page on Hulk Hogan's wrestling legacy Judge delays TPS program termination for migrants from Honduras, Nepal and Nicaragua Solve the daily Crossword
